1. 134 Long-Term Deutetrabenazine Treatment Is Associated with Sustained Treatment Response in Tardive Dyskinesia: Results from an Open-Label Extension Study. (April 2020) Authors: Hauser, Robert A.; Barkay, Hadas; Fernandez, Hubert H.; Factor, Stewart A.; Jimenez-Shahed, Joohi; Gross, Nicholas; Marinelli, Leslie; Forrest Gordon, Mark; Savola, Juha-Matti; Anderson, Karen E. Journal: CNS spectrums Issue: Volume 25:Number 2(2020) Page Start: 284 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 151 Confirmed Safety of Deutet.rabenazine for Tardive Dyskinesia in a 3-Year Open-Label Extension Study. (April 2020) Authors: Fernandez, Hubert H.; Barkay, Hadas; Hauser, Robert A.; Factor, Stewart A.; Jimenez-Shahed, Joohi; Gross, Nicholas; Marinelli, Leslie; Gordon, Mark Forrest; Savola, Juha-Matti; Anderson, Karen E. Journal: CNS spectrums Issue: Volume 25:Number 2(2020) Page Start: 296 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 35 Long-term Improvements in Site-Rated Outcomes with Deutetrabenazine Treatment in Patients with Tardive Dyskinesia. (12th March 2019) Authors: Anderson, Karen E.; Stamler, David; Davis, Mat D.; Gross, Nicholas; Hauser, Robert A.; Jarskog, L. Fredrik; Jimenez-Shahed, Joohi; Kumar, Rajeev; Ochudlo, Stanislaw; McEvoy, Joseph; Fernandez, Hubert H. Journal: CNS spectrums Issue: Volume 24:Number 1(2019:Feb) Page Start: 193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Central nervous system effects of the histamine‐3 receptor antagonist CEP‐26401, in comparison with modafinil and donepezil, after a single dose in a cross‐over study in healthy volunteers. Issue 5 (14th March 2019) Authors: Baakman, Anne C.; Zuiker, Rob; van Gerven, Joop M.A.; Gross, Nicholas; Yang, Ronghua; Fetell, Michael; Gershon, Ari; Gilgun‐Sherki, Yossi; Hellriegel, Edward; Spiegelstein, Ofer Journal: British journal of clinical pharmacology Issue: Volume 85:Issue 5(2019) Page Start: 970 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effects of Long-Term Deutetrabenazine Treatment in Patients with Tardive Dyskinesia and Underlying Psychiatric or Mood Disorders. (April 2022) Authors: Hauser, Robert A.; Barkay, Hadas; Fernandez, Hubert H.; Factor, Stewart A.; Jimenez-Shahed, Joohi; Gross, Nicholas; Marinelli, Leslie; Wilhelm, Amanda; Gordon, Mark Forrest; Savola, Juha-Matti; Anderson, Karen E. Journal: CNS spectrums Issue: Volume 27:Number 2(2022) Page Start: 245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington's Disease. (April 2021) Authors: Frank, Samuel; Vaughan, Christina; Stamler, David; Oakes, David; Davis, Mat D.; Gross, Nicholas; Gordon, Mark Forrest; Savola, Juha-Matti; Wieman, Maria; Eberly, Shirley; Kayson, Elise; Whaley, Jacquelyn; Goldstein, Jody; Testa, Claudia M. Journal: CNS spectrums Issue: Volume 26:Number 2(2021) Page Start: 162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long-Term Deutetrabenazine Treatment Is Associated With Continued Improvement in Tardive Dyskinesia in the Completed 3-Year Open-Label Extension Study. (April 2021) Authors: Hauser, Robert A.; Barkay, Hadas; Fernandez, Hubert H.; Factor, Stewart A.; Jimenez-Shahed, Joohi; Gross, Nicholas; Marinelli, Leslie; Wilhelm, Amanda; Gordon, Mark Forrest; Savola, Juha-Matti; Anderson, Karen E. Journal: CNS spectrums Issue: Volume 26:Number 2(2021) Page Start: 162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Long-Term Efficacy and Safety of Deutetrabenazine in Patients with Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonist Use. (April 2022) Authors: Hauser, Robert A.; Barkay, Hadas; Fernandez, Hubert H.; Factor, Stewart A.; Jimenez-Shahed, Joohi; Gross, Nicholas; Marinelli, Leslie; Wilhelm, Amanda; Gordon, Mark Forrest; Savola, Juha-Matti; Anderson, Karen E. Journal: CNS spectrums Issue: Volume 27:Number 2(2022) Page Start: 246 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia. (April 2021) Authors: Sajatovic, Martha; Wilhelm, Amanda; Finkbeiner, Stacy; Barkay, Hadas; Chaijale, Nayla; Gross, Nicholas; Gordon, Mark Forrest Journal: CNS spectrums Issue: Volume 26:Number 2(2021) Page Start: 157 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Issue 2 (February 2019) Authors: Reilmann, Ralf; McGarry, Andrew; Grachev, Igor D; Savola, Juha-Matti; Borowsky, Beth; Eyal, Eli; Gross, Nicholas; Langbehn, Douglas; Schubert, Robin; Wickenberg, Anna Teige; Papapetropoulos, Spyros; Hayden, Michael; Squitieri, Ferdinando; Kieburtz, Karl; Landwehrmeyer, G Bernhard Journal: Lancet neurology Issue: Volume 18:Issue 2(2019) Page Start: 165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗